{"id":900753,"date":"2025-10-27T16:33:30","date_gmt":"2025-10-27T20:33:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/"},"modified":"2025-10-27T16:33:30","modified_gmt":"2025-10-27T20:33:30","slug":"immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/","title":{"rendered":"Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Oct.  27, 2025  (GLOBE NEWSWIRE) &#8212; Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.<\/p>\n<p>To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ohi8WLTIDDGM2Sz49v2gx_2BW4WZ21BY2pcoMNEMGdIiY32A2HAgBDT0S1EGzL1w8b0YfL2iewkD5d-wCjEzPNBS7bv7gGK_9L4P95agc0AlkqYl-behAP3-xpyKyxZXout71OJil5_DBvJiipNlgHrMZAy5-2rlEbPoiaNRTfk=\" rel=\"nofollow\" target=\"_blank\"><u>registration link<\/u><\/a>. The presentation and webcast details will also be available under \u201cNews &amp; Events\u201d in the Investors section of the Immunovant website at https:\/\/www.immunovant.com\/investors\/news-events\/ir-calendar. The archived webcast will be available on Immunovant\u2019s website after the conference call.<\/p>\n<p>\n        <strong>About Immunovant <\/strong><br \/>\n        <br \/>Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PACj4q6oqROiX03gpmYGBnXs9OzIhLuwfwcRIM8RZd2s6WScrA53MIjZYi4dOF9gI2RcWpCc3eiAVv1TA8Qlt5p0hXNB6NdAJYE07NjMUlsSraHsnmDao3Y9iTUD79MyzM7uGVvdHywojNu2RizK_ICgXJ2fxrhSv6Wufvo7N4TM2vOY0ODEOZw2FCLUll4vpEwZW_TcN-jP7-LWrBvYNPenXTK_pF972yj9dmEcVEo=\" rel=\"nofollow\" target=\"_blank\"><strong>immunovant.com<\/strong><\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>\n        <u>Investors<\/u><br \/>\n        <br \/>Keyur Parekh<br \/>keyur.parekh@roivant.com<\/p>\n<p>\n        <u>Media<\/u><br \/>\n        <br \/>Stephanie Lee<br \/>stephanie.lee@roivant.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjgwOCM3MjI1OTIyIzIxMjU4NDQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmMyMTFkMDktMTE0Ny00MmRiLTkyMDItNmUxODllMjcwY2FjLTExMzc0MTUtMjAyNS0xMC0yNy1lbg==\/tiny\/Immunovant-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) &#8212; Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under \u201cNews &amp; Events\u201d in the Investors section of the Immunovant website at https:\/\/www.immunovant.com\/investors\/news-events\/ir-calendar. The archived webcast will be available on Immunovant\u2019s website after the conference call. About Immunovant Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-900753","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) &#8212; Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under \u201cNews &amp; Events\u201d in the Investors section of the Immunovant website at https:\/\/www.immunovant.com\/investors\/news-events\/ir-calendar. The archived webcast will be available on Immunovant\u2019s website after the conference call. About Immunovant Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, &hellip; Continue reading &quot;Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T20:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjgwOCM3MjI1OTIyIzIxMjU4NDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025\",\"datePublished\":\"2025-10-27T20:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/\"},\"wordCount\":181,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MjgwOCM3MjI1OTIyIzIxMjU4NDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/\",\"name\":\"Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MjgwOCM3MjI1OTIyIzIxMjU4NDQ=\",\"datePublished\":\"2025-10-27T20:33:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MjgwOCM3MjI1OTIyIzIxMjU4NDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2MjgwOCM3MjI1OTIyIzIxMjU4NDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/","og_locale":"en_US","og_type":"article","og_title":"Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 - Market Newsdesk","og_description":"NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) &#8212; Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025. To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under \u201cNews &amp; Events\u201d in the Investors section of the Immunovant website at https:\/\/www.immunovant.com\/investors\/news-events\/ir-calendar. The archived webcast will be available on Immunovant\u2019s website after the conference call. About Immunovant Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, &hellip; Continue reading \"Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-27T20:33:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjgwOCM3MjI1OTIyIzIxMjU4NDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025","datePublished":"2025-10-27T20:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/"},"wordCount":181,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjgwOCM3MjI1OTIyIzIxMjU4NDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/","name":"Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjgwOCM3MjI1OTIyIzIxMjU4NDQ=","datePublished":"2025-10-27T20:33:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjgwOCM3MjI1OTIyIzIxMjU4NDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2MjgwOCM3MjI1OTIyIzIxMjU4NDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunovant-to-report-financial-results-for-the-second-quarter-ended-september-30-2025-and-provide-business-update-on-monday-november-10-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=900753"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900753\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=900753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=900753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=900753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}